EMA Recommends Breast Cancer Treatment

EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended the drug based on two Phase III trials. One study compared treatment with palbociclib and letrozole, an aromatase inhibitor, with letrozole treatment alone. Four hundred and forty-four patients lived on average 24.8 months without their disease getting worse, compared to 14.5 months in the group of 222 patients that received letrozole alone. The other trial compared treatment of fulvestrant together with palbociclib to treatment with only fulvestrant. Preliminary results showed that 347 out of 521 patients who received palbociclib had an average of 11.2 months without their disease getting worse compared to 4.6 months for 174 patients who only received fulvestrant.

Ibrance (palbociclib) blocks cyclin-dependent kinases (CDK) 4 and 6 protein, which inhibits cancer cells and tumor growth. It is used in postmenopausal women in combination with an aromatase inhibitor or with fulvestrant for women who have undergone hormone therapy. For premenopausal women, the hormone therapy is combined with a luteinizing hormone releasing hormone (LHRH).

Source